134 related articles for article (PubMed ID: 15757864)
1. Distinction in gene expression profiles demonstrated in parathyroid adenomas by high-density oligoarray technology.
Forsberg L; Björck E; Hashemi J; Zedenius J; Höög A; Farnebo LO; Reimers M; Larsson C
Eur J Endocrinol; 2005 Mar; 152(3):459-70. PubMed ID: 15757864
[TBL] [Abstract][Full Text] [Related]
2. Loss of heterozygosity in sporadic parathyroid tumours: involvement of chromosome 1 and the MEN1 gene locus in 11q13.
Dwight T; Twigg S; Delbridge L; Wong FK; Farnebo F; Richardson AL; Nelson A; Zedenius J; Philips J; Larsson C; Teh BT; Robinson B
Clin Endocrinol (Oxf); 2000 Jul; 53(1):85-92. PubMed ID: 10931084
[TBL] [Abstract][Full Text] [Related]
3. Frequent loss of heterozygosity at 1p36.3 and p73 abnormality in parathyroid adenomas.
Shan L; Yang Q; Nakamura Y; Nakamura M; Miyauchi A; Tsujimoto M; Nakatani Y; Wakasa K; Mori I; Kakudo K
Mod Pathol; 2001 Apr; 14(4):273-8. PubMed ID: 11301342
[TBL] [Abstract][Full Text] [Related]
4. Deletion of 11q23 and cyclin D1 overexpression are frequent aberrations in parathyroid adenomas.
Hemmer S; Wasenius VM; Haglund C; Zhu Y; Knuutila S; Franssila K; Joensuu H
Am J Pathol; 2001 Apr; 158(4):1355-62. PubMed ID: 11290553
[TBL] [Abstract][Full Text] [Related]
5. Differential expression of the calcium sensing receptor and combined loss of chromosomes 1q and 11q in parathyroid carcinoma.
Haven CJ; van Puijenbroek M; Karperien M; Fleuren GJ; Morreau H
J Pathol; 2004 Jan; 202(1):86-94. PubMed ID: 14694525
[TBL] [Abstract][Full Text] [Related]
6. Differential loss of heterozygosity in familial, sporadic, and uremic hyperparathyroidism.
Farnebo F; Teh BT; Dotzenrath C; Wassif WS; Svensson A; White I; Betz R; Goretzki P; Sandelin K; Farnebo LO; Larsson C
Hum Genet; 1997 Mar; 99(3):342-9. PubMed ID: 9050920
[TBL] [Abstract][Full Text] [Related]
7. A possible tumor suppressor gene for parathyroid adenomas.
Iwasaki H
Int Surg; 1996; 81(1):71-6. PubMed ID: 8803711
[TBL] [Abstract][Full Text] [Related]
8. Aryl hydrocarbon receptor interacting protein (AIP) mutations occur rarely in sporadic parathyroid adenomas.
Pardi E; Marcocci C; Borsari S; Saponaro F; Torregrossa L; Tancredi M; Raspini B; Basolo F; Cetani F
J Clin Endocrinol Metab; 2013 Jul; 98(7):2800-10. PubMed ID: 23633209
[TBL] [Abstract][Full Text] [Related]
9. Cytogenetic and molecular analyses of multiple endocrine neoplasias of the MEN1 syndrome.
Pourani J; Kaserer K; Pfragner R
Int J Oncol; 2002 May; 20(5):971-6. PubMed ID: 11956591
[TBL] [Abstract][Full Text] [Related]
10. RAD51 as a candidate parathyroid tumour suppressor gene on chromosome 15q: absence of somatic mutations.
Carling T; Imanishi Y; Gaz RD; Arnold A
Clin Endocrinol (Oxf); 1999 Oct; 51(4):403-7. PubMed ID: 10583305
[TBL] [Abstract][Full Text] [Related]
11. Distinct target regions for chromosome 1p deletions in parathyroid adenomas and carcinomas.
Välimäki S; Forsberg L; Farnebo LO; Larsson C
Int J Oncol; 2002 Oct; 21(4):727-35. PubMed ID: 12239610
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathogenesis of primary hyperparathyroidism.
Arnold A; Shattuck TM; Mallya SM; Krebs LJ; Costa J; Gallagher J; Wild Y; Saucier K
J Bone Miner Res; 2002 Nov; 17 Suppl 2():N30-6. PubMed ID: 12412775
[TBL] [Abstract][Full Text] [Related]
13. Multiple endocrine neoplasia type 1 (MEN1) gene mutations in a subset of patients with sporadic and familial primary hyperparathyroidism target the coding sequence but spare the promoter region.
Karges W; Jostarndt K; Maier S; Flemming A; Weitz M; Wissmann A; Feldmann B; Dralle H; Wagner P; Boehm BO
J Endocrinol; 2000 Jul; 166(1):1-9. PubMed ID: 10856877
[TBL] [Abstract][Full Text] [Related]
14. Frequent loss of chromosome arm 1p DNA in parathyroid adenomas.
Cryns VL; Yi SM; Tahara H; Gaz RD; Arnold A
Genes Chromosomes Cancer; 1995 May; 13(1):9-17. PubMed ID: 7541648
[TBL] [Abstract][Full Text] [Related]
15. Parathyroid MEN1 gene mutations in relation to clinical characteristics of nonfamilial primary hyperparathyroidism.
Carling T; Correa P; Hessman O; Hedberg J; Skogseid B; Lindberg D; Rastad J; Westin G; Akerström G
J Clin Endocrinol Metab; 1998 Aug; 83(8):2960-3. PubMed ID: 9709976
[TBL] [Abstract][Full Text] [Related]
16. Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study.
Hsi ED; Zukerberg LR; Yang WI; Arnold A
J Clin Endocrinol Metab; 1996 May; 81(5):1736-9. PubMed ID: 8626826
[TBL] [Abstract][Full Text] [Related]
17. Genomic localization of novel candidate tumor suppressor gene loci in human parathyroid adenomas.
Tahara H; Smith AP; Gas RD; Cryns VL; Arnold A
Cancer Res; 1996 Feb; 56(3):599-605. PubMed ID: 8564978
[TBL] [Abstract][Full Text] [Related]
18. Genetic and clinical characterization of sporadic cystic parathyroid tumours.
Villablanca A; Farnebo F; Teh BT; Farnebo LO; Höög A; Larsson C
Clin Endocrinol (Oxf); 2002 Feb; 56(2):261-9. PubMed ID: 11874419
[TBL] [Abstract][Full Text] [Related]
19. Whole-exome sequencing studies of nonhereditary (sporadic) parathyroid adenomas.
Newey PJ; Nesbit MA; Rimmer AJ; Attar M; Head RT; Christie PT; Gorvin CM; Stechman M; Gregory L; Mihai R; Sadler G; McVean G; Buck D; Thakker RV
J Clin Endocrinol Metab; 2012 Oct; 97(10):E1995-2005. PubMed ID: 22855342
[TBL] [Abstract][Full Text] [Related]
20. Promoter hypermethylation inactivates CDKN2A, CDKN2B and RASSF1A genes in sporadic parathyroid adenomas.
Arya AK; Bhadada SK; Singh P; Sachdeva N; Saikia UN; Dahiya D; Behera A; Bhansali A; Rao SD
Sci Rep; 2017 Jun; 7(1):3123. PubMed ID: 28600574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
